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ABSTRACT
HIV-1 Tat protein reprograms cellular gene expres-
sion of infected as well as uninfected cells apart
from its primary function of transactivating HIV-1
long terminal repeat (LTR) promoter by binding to a
nascent RNA stem±loop structure known as the
transactivator response region (TAR). Tat also
induces chromatin remodeling of proviral LTR-medi-
ated gene expression by recruiting histone acetyl
transferases to the chromatin, which results in his-
tone acetylation. Furthermore several studies have
shown convincing evidence that Tat can transacti-
vate HIV-1 gene expression in the absence of TAR,
the molecular mechanism of which remains to be
elucidated. Here we show a direct interaction of Tat
with nuclear factor kappa B (NFkB) enhancer, a
global regulatory sequence for many cellular genes
both in vitro and in vivo. This interaction not only
provides a novel molecular basis to explain TAR-
independent transactivation in HIV-1, but also
points toward the potential mechanism of Tat-
mediated modulation of cellular genes.
INTRODUCTION
The transactivator protein Tat of human immunode®ciency
virus-1 (HIV-1) is the most important regulator of viral gene
expression and replication (1,2). Tat has been shown to
activate long terminal repeat (LTR) promoter directed tran-
scription by interacting with nascent RNA stem±loop struc-
tures, present immediately downstream of the initiation
sequence known as the transactivation response region
(TAR) (3,4), and subsequent assembly of positive transcrip-
tion elongation factor b (pTEFb) (5). This activity is
dependent on various cellular (6) and viral factors (7)
including cyclin T1 and Tat-activated kinase (TAK) (8),
which forms a ternary complex via metal ion coordination (9).
Tat has been shown to be involved in both initiation and
elongation of transcription (2,3,10). It is also known to induce
chromatin remodeling (11) by recruiting histone acetyl
transferases (HATs) such as p300 and p300/CBP associated
protein P/CAF to the chromatin (11±13), which results in
histone acetylation (14) and acetylation of itself (15). In
addition, several studies have shown convincing evidence that
Tat can transactivate HIV-1 gene expression in the absence of
TAR (16±18). It has also been shown that NFkB regulatory
elements in the enhancer region of LTR play an important role
in TAR-independent transactivation but the molecular basis of
this activation remains to be clearly understood (18,19).
Furthermore, an absolute requirement of NFkB enhancer
element was shown for both Tat-dependent and Tat-inde-
pendent viral transcription in blood CD4 T cells (20). TAR-
independent transactivation of LTR by Tat illuminates the
complexity underlying the modulation of viral and cellular
promoters, suggestive of potential pathways responsible for its
multiple functions.
The overview of the molecular activities of Tat clearly
indicates that, far beyond an HIV-1 speci®c transcriptional
transactivator, the protein acts as a pleiotropic factor for a
number of functions both inside and outside the cell (6). Tat
protein through transcellular communication reprograms
cellular gene expression of infected as well as uninfected
cells and may contribute to a wide range of clinical
complications (21). It has been shown to modulate a number
of cellular genes and make the cellular environment amenable
for viral replication (6). A number of earlier studies clearly
indicate that Tat could substantially affect transcription when
tethered to DNA (18,22). There have also been reports
establishing functional similarities between Tat and other
transcription factors (23) which enhance the level of gene
expression by binding to DNA. It is also established that Tat
exist as a metal ion (Zn2+or Cd2+)-linked dimer bridging
cysteine-rich regions of each monomer, a characteristic of
DNA binding proteins (24). In addition, Tat is shown to
modulate and de-repress the integrated HIV-1 chromatin
structure, aiding in activation of transcription; however, NFkB
alone fails to stimulate the integrated transcriptionally silent
HIV-1 promoter (25,26). Interestingly, Tat is unable either to
activate transcription or to induce changes in the chromatin
structure of an integrated promoter lacking both Sp1 and
NFkB sites even when it is tethered to the HIV-1 core
promoter upstream of the TATA box (25), indicating thereby
the importance of this region in LTR driven viral gene
expression in infected cells.
All this information leads us to ask whether Tat could
interact with DNA, speci®cally with upstream enhancer
sequences in LTR, which has been shown to be important
for both TAR-independent and TAR-dependent Tat-
responsive transactivation of HIV-1 LTR. In this report we
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demonstrate for the ®rst time a direct interaction of Tat both
in vitro and in vivo with NFkB enhancer element, which has
previously been suspected to be a critical element for TAR-
independent transactivation by Tat.
MATERIALS AND METHODS
Oligonucleotides and Tat protein
Consensus NFkB, AP1 and SP1 oligonucleotides were
obtained from Promega (USA). All other oligonucleotides
were custom synthesized using b-cynoethyl phosphoramidite
chemistry on either Pharmacia Gene Assembler plus auto-
mated synthesizer (Pharmacia, USA) or ABI 3900 DNA
synthesizer (Applied Biosystems, USA). Oligonucleotides
were puri®ed to more than 95% purity on a C18 reverse phase
HPLC column using triethyl ammonium acetate buffer.
Recombinant pure Tat was obtained from the NIH AIDS
Reagent Program (27) or puri®ed from Escherichia coli BL21-
DE3 transformed with expression vector GST-Tat 1-86R TK
and GST-Tat 1-86 C22G mutant (28) as reported, with minor
modi®cations. The GST-Tat bound glutathione±Sepharose
beads (Amersham, USA) were treated with thrombin
(Amersham, USA) in PBS pH 7.4 to cleave the fusion tag.
The protein was further puri®ed by reverse phase FPLC on a
C4 column with water:acetonitrile and 0.1 % tri¯uroacetic
acid buffer, and purity was checked by C18 reverse phase
HPLC and SDS±PAGE followed by silver staining and
western blot analysis. The polyclonal Tat antibody (29) that
has been reported to work well in both immunoprecipitation
and western blot (7) was obtained from the NIH AIDS
Reagent Program.
Cell cultures and preparation of nuclear extract
HEK 293T and Jurkat (J6) T-cell lines were obtained from the
Cell Repository, National Centre for Cell Science, India.
CEM-GFP, a reporter T-cell line, was obtained from the NIH
AIDS Repository (30). HEK 293T cells were grown in
Dulbecco's modi®ed Eagle's medium (Gibco-BRL, USA),
CEM-GFP cells and Jurkat cells were grown in RPMI 1640
(Gibco-BRL, USA) supplemented with 10% fetal bovine
serum (Gibco-BRL, USA) at 37°C in 5% CO2. The nuclear
extract of Jurkat cells activated with 50 ng/ml of phorbol 12-
myristate 13-acetate (PMA) (Sigma, USA) or untreated cells
was prepared essentially as described earlier (31).
HIV-1 infection and transfection
The CEM-GFP cell line was infected with HIV-1 NL4.3 virus
isolate (32) using 100 ng of p24 units per 2 3 106 cells as
described previously (33). A reporter vector expressing
luciferase under ®ve tandem copies of NFkB enhancer,
pNFkB-Luc, was obtained from Stratagene (USA). The
HIV-1 Tat encoding expression vector pCDNA-Tat, has
been described previously (7). The 1±48 truncated Tat gene
was cloned in pCDNA3.1 by subcloning the sequence from
the pCDNA-Tat vector described above using PCR. Jurkat
cells were stably transfected with pCDNA-Tat using electro-
poration and the cells were incubated with geneticin (G418
sulfate; Gibco-BRL, USA) 1000 mg/ml for selecting Tat-
expressing Jurkat cells. Reverse transcription PCR and
transactivation assay using HIV-1 LTR-luciferase vector
con®rmed the expression of Tat in these Jurkat-Tat cells.
Nuclear extracts from Jurkat-Tat cells were prepared as
mentioned above. HEK 293T cells were plated at a density of
6 3 105 cells/well in a six-well plate. The cells were allowed
to adhere to the plate and subsequently plasmid vectors were
transfected with Lipofectamine 2000 (Gibco-BRL, USA)
according to the manufacturer's instructions.
Gel shift assay
Complementary strands of oligonucleotides were annealed to
generate double-stranded oligonucleotides for gel shift assay
by heating equimolar amounts at 94°C for 2 min and
subsequently gradually cooling to room temperature in a
water bath (Table 1). Oligonucleotides were end-labeled with
[g-33P]ATP (BRIT, India) and 10 U of T4 polynucleotide
kinase (Gibco-BRL, USA) using a forward reaction buffer
according to the manufacturer's instruction. Radiolabeled
probes (0.02 pmol) were incubated with 2.5 mg of pure Tat
protein, unless indicated otherwise, in 10 mM HEPES pH 7.9,
50 mM KCl, 1 mM dithiothreitol (DTT), 2 mg/ml poly dI-
dC:dI-dC, 330 mg/ml BSA and 10% (w/v) glycerol at 30°C for
10 min and loaded onto 9% native PAGE (acrylamide:bisa-
crylamide, 50:1) containing 5% glycerol. The gel was
electrophoresed in 0.53 TBE at 150 V for 45 min at 4°C in
a Bio-Rad protean II gel electrophoresis system. The gel was
dried and exposed to Kodak Biomax ®lm with intensifying
screen. A competition assay was carried out using 100- and
200-fold molar excess of cold speci®c or mutated oligonu-
cleotide. Supershift was done using anti-Tat antibody (29) and
anti-p65 antibody (Santa Cruz, USA).
Oligo library screening
The synthetic random oligonucleotide library (DDSEL) with
two ®xed primer regions (5¢ DDCI and 3¢ DDCII) and a central
random 32-base region was synthesized using the reported
procedure (34). The oligonucleotide library was desalted and
used without any further puri®cation. One hundred nanograms
of DDSEL was labeled with [a-32P]dATP (BRIT, India) using
an E.coli Klenow fragment (Roche, USA) according to the
manufacturer's instruction. The selection of bound oligonu-
Table 1. List of oligonucleotides used in gel shift assay
Sr. no. Sequence Region (position)
1 5¢ CAAGGGACTTTCCGCTGGGGACTTTCCAGG NFkB enhancer from HIV-1 LTR (347±376)
2 5¢ CAACTCGGTTTCCGCTCTCAGCTTTCCAGG Mutated NFkB enhancer from HIV-1 LTR
3 5¢ AGTTGAGGGGACTTTCCCAGGC NFkB consensus
4 5¢ AGTTGACTCTCAGATGATAGGC Mutated NFkB consensus
5 5¢ ATTCGATCGGGGCGGGGCGAGC SP1 consensus
6 5¢ CGCTTGATGAGTCAGCCGGAA AP1 consensus
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cleotides was done after incubation with GST-Tat protein
followed by gel shift as described above. The bound
oligonucleotides were gel extracted using the crush and soak
method. The gel-extracted band was radiolabeled during
ampli®cation by PCR using DDCI and DDCII primers in the
presence of [a-32P]dATP. This product was used for the next
round of selection following the same protocol. Five rounds of
iterative selection were carried out by gel shift and the
enriched library was cloned into pGEM-T Easy vector
(Promega, USA) according to the manufacturer's instructions
and transformed into chemically competent E.coli DH5a.
Fourteen positive clones were selected and sequenced.
Circular dichroism (CD)
CD spectra were collected on a Jasco-715 spectropolarimeter
using a 1 nm bandwidth. CD spectra were averaged for 10
accumulations at a scan speed of 100 nm/min to improve the
signal-to-noise ratio. A quartz cell with a pathlength of 0.10
cm was used for all measurements. All spectra were collected
by dilution of the protein and oligonucleotides in PBS pH 7.4.
Chromatin immunoprecipitation (CHIP) assay
The CHIP assay was done as described (35,36) with minor
modi®cations. Brie¯y, HIV-1 NL4.3-infected CEM-GFP cells
were cross-linked by 1% formaldehyde followed by quench-
ing with 125 mM glycine. Cells were washed and the pellet
was lysed in lysis buffer [150 mM NaCl, 25 mM Tris±HCl pH
7.5, 5 mM EDTA pH 8.0, 1% Triton X-100, 0.1% SDS, 0.5%
sodium deoxycholate, 1 mM PMSF, 10 mM sodium butyrate,
13 protease inhibitor cocktail (Roche)], followed by sonica-
tion. The sonicated lysate was precleared by incubation with
protein A/G beads, salmon sperm DNA and BSA followed by
centrifugation. This supernatant was used as the input sample
for immunoprecipitation with anti-Tat antibody or isotype
control by incubation at 4°C overnight. The chromatin
antibody complex was immobilized on protein A/G beads
and then eluted in 2% SDS, 0.1 M NaHCO3 and 10 mM DTT.
Cross-links were reversed and the protein was digested with
proteinase K (100 mg/ml). DNA was recovered by phenol±
chloroform extraction and ethanol precipitation. Precipitated
DNA was dissolved in water and analyzed by PCR (30 cycles:
94°C for 1 min, 55°C for 1 min, 72°C for 1 min) with the LTR
speci®c primers described in Table 2. The PCR products were
analyzed on 1% agarose gel and visualized by ethidium
bromide staining.
RESULTS
Although the previous reports point toward the possibility of a
DNA binding activity of Tat (18,22,23), to the best of our
knowledge it has not been shown experimentally. In order to
identify the presence of DNA binding activity in Tat protein,
we started with an alignment search for Tat sequence against
superfamilies of protein, based on the structural classi®cation
of proteins using the hidden Markov model (37) with software
Superfamily 1.61 (http://www.supfam.org). This examination
of HIV-1 Tat protein suggested that it contained structural
motifs homologous to the N-terminal domain of the mouse
and human NFkB p50 subunit (Fig. 1) and that it belongs to
the p53 superfamily of transcription factors. This similarity in
structural motif could be due to the presence of structurally
conserved amino acid residues like Val (4th), Cys (22nd) Leu-
Gly-Iso (43rd to 45th) and Lys-Lys (50th to 51st).
Based on previous reports and our structural alignment
results mentioned above, we used gel shift assay to identify the
DNA binding activity of puri®ed recombinant Tat protein with
NFkB enhancer sequences. As shown in Figure 2A, Tat
protein speci®cally binds to NFkB consensus sequence, which
is competed out by cold speci®c oligo but not by mutated
oligo. Tat binding to the DNA was further con®rmed by a
supershift using Tat antibody (Fig. 2A, lane 6). Then we used
the oligonucleotide sequence present in the HIV-1 LTR
representing the NFkB enhancer sequence (Table 1) for Tat
interaction in gel shift assays. Again, Tat speci®cally bound
the wild-type LTR NFkB while no binding was observed with
a mutated oligo (Fig. 2B). To establish the speci®city of this
binding, we performed gel shift assay with two additional
enhancer oligonucleotides present in the HIV-1 LTR, AP1 and
SP1. Neither of these sequences showed any interaction with
Tat protein although they interacted with the cellular proteins
present in nuclear extract (Fig. 2C), demonstrating thereby the
speci®city of Tat-NFkB enhancer interaction. Also, enhance-
ment in Tat±NFkB binding was observed in the presence of
ZnCl2 (Fig. 2D).
Table 2. List of oligonucleotide primers used in CHIP assay
Sr.
no.
Sequence Region (position)
1 5¢ CCTGCATGGAATGGATGACC HIV-1 LTR forward (218±237)
2 5¢ CGCCCAGGCACGCTCC HIV-1 LTR reverse (376±393)
3 5¢ CGAACAGGGACTTGAAAGC HIV-1 LTR forward (643±661)
4 5¢ CATCTCTCTCCTTCTAGCCTC HIV-1 LTR reverse (772±792)
Figure 1. Multiple alignment of sequence obtained from SCOP database
searches with Superfamily version 1.61. Tat protein aligns with a p53-like
transcription factor superfamily with maximal homology to the N-terminal
domain of mouse and human NFkB p50 (model number 0003904;
expectation value, 2.9 3 10±0.1). The proteins are identi®ed by PDB entry
codes on the left-hand side of the alignment. The following proteins show
alignment: mouse NFkB p50 dimer (1nfk), human NFkB p50 dimer (1svc),
chicken c-Rel dimer (1gji), mouse NFkB p65 dimer (2ram), mouse NFkB
p65 p50 human IkB complex (1ikn), human NFkB p65 p50 human IkB
complex (1n®), mouse NFkB p65 p50 dimer (1vkx) and Anopheles gambif1
dimer (1bvo).
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In order to check whether NFkB enhancer sequence could
bind to Tat in the presence of NFkB protein in nuclear extract,
we then studied the binding of LTR-NFkB probe with the
nuclear extract prepared from Jurkat-Tat cells expressing Tat
endogenously. The Jurkat-Tat nuclear extract gave shifted
complexes with LTR-NFkB probe, which seems to comprise
both Tat and NFkB bound shifted complexes, as evidenced by
supershift with both Tat and p65 (NFkB) antibody (Fig. 3A).
In the control experiment only an NFkB-mediated shift was
observed in untransfected Jurkat nuclear extract (Fig. 3B),
whereas Tat antibody did not show any supershift (Fig. 3C).
Finally, only wild-type Tat (1±86 amino acids) protein could
bind to the LTR NFkB probe while a transactivation negative
mutant of Tat C22G failed to interact, indicating again the
speci®city of the binding of Tat protein to the NFkB enhancer
sequence (Fig. 3D).
In order to verify this NFkB enhancer DNA and Tat protein
interaction independently, we also screened an oligonucleo-
tide library using SELEX technology. Iterative screening of
the oligonucleotide library was carried out to determine the
consensus binding motif for Tat protein. The sequences
internal to the primer in the selected sequences (Table 3) were
analyzed using the motif discovery tool MEME (Multiple EM
for Motif Elicitation) software version 3.0 (http://meme.sdsc.
edu/) (38) to identify a 15 bp motif bound by Tat protein with
the experimentally obtained sequences. The multilevel con-
sensus sequence generated by the matrix obtained from the
software is shown in Figure 4, which corresponds closely to
the complementary NFkB consensus enhancer sequence. The
above interaction was further con®rmed by recording CD
spectra of Tat protein alone and after incubation with LTR
NFkB wild-type and mutated oligonucleotides. We observed a
negative band at 208 nm, which on addition of wild-type LTR
oligonucleotide was reduced in intensity (Fig. 5). This change
is not observed with mutated oligonucleotide and is also not
due to a simple additive effect of the spectra of DNA and
protein, since the computer addition spectra were different
from the spectra of the complex. This de®nite change in
signature supported speci®c interaction of NFkB enhancer
sequence and Tat protein.
The above mentioned experiments clearly indicate the
presence of NFkB enhancer binding activity of Tat protein
in vitro. Previous transactivation studies using wild-type and
TAR-deleted LTR reporter constructs by several laboratories
have unequivocally pointed toward the importance of NFkB
enhancer sequence of LTR in TAR-independent transactiva-
tion (16±19), but the effect of Tat on isolated NFkB enhancer
has not been studied. The in vivo role of the observed Tat-
NFkB DNA binding was established by transient transfection
studies in the HEK 293T cell line. A dose-dependent increase
Figure 2. Tat interacts speci®cally with NFkB enhancer sequences. (A) Gel shift assay using NFkB consensus oligonucleotide as labeled probe and cold
speci®c and mutated oligonucleotide as competitors. The sequences are given in Table 1. Lane 1, free probe; lane 2, Tat protein; lane 3, 100-fold excess of
cold speci®c oligonucleotide; lane 4, 200-fold excess of cold speci®c oligonucleotide; lane 5, 200-fold excess mutated oligonucleotide; lane 6, supershift with
anti-Tat antibody. (B) Gel shift assay using wild-type and mutated HIV-1 LTR NFkB oligonucleotides (Table 1) as labeled probe. Lane 1, free wild-type
oligo; lane 2, Tat; lane 3, free mutated oligo; lane 4, Tat. (C) Gel shift assay using AP1 and SP1 consensus oligonucleotides (Table 1) with Tat protein and
Jurkat nuclear extracts. Lanes 1±4 depict use of AP1 and lanes 5±8 shows use of SP1 consensus oligonucleotide. Lane 1, free probe AP1; lane 2, nuclear
extract of Jurkat; lane 3, nuclear extract from activated Jurkat; lane 4, Tat; lane 5, free probe SP1, lane 6, nuclear extract of Jurkat; lane 7, nuclear extract
from activated Jurkat; lane 8, Tat. (D) Gel shift showing enhancement of Tat binding to HIV-1 LTR NFkB oligonucleotide in the presence of 1.25 mM
ZnCl2. Lane 1, free probe; lane 2, Tat (500 ng) in presence of Zn2+ cations; lane 3, Tat (500 ng).
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of up to ~8-fold in reporter activity (Fig. 6) of NFkB enhancer
driven luciferase (pNFkB-luc) construct was observed on co-
transfection with Tat expression vector pCDNA-Tat. This
activity was obliterated when the reporter plasmid was
co-transfected with pCDNA encoding truncated 1±48 Tat
mutant (Fig. 6), which is known to be devoid of the nuclear
localization signal and nucleic acid binding motif (2). In
addition to the TAR-independent transcriptional activation of
HIV-1 LTR, the observed increase in the NFkB driven
reporter activity is of particular importance as a possible
mechanism for Tat-mediated modulation of cellular gene
function. In order to identify the presence of Tat binding to
NFkB enhancer in vivo, we then performed a CHIP assay
using HIV-1 NL4.3-infected CEM-GFP cells. The presence of
LTR-containing genomic sequences bound to Tat protein was
analyzed by formaldehyde cross-linking of HIV-infected cells
followed by chromatin immunoprecipitation of HIV-infected
cells by Tat antibody. Figure 7A represents the cross-linked
DNA±protein complex sheared by sonication (input sample)
prior to immunoprecipitation. PCR ampli®cation with LTR
speci®c primers ¯anking the NFkB enhancer region between
nuc-0 and nuc-1 yielded a speci®c 175 bp product in
chromatin immunoprecipitated with Tat antibody, while no
detectable product band was found with isotype antibody
control (Fig. 7B). To rule out any nonspeci®c ampli®cation, a
Figure 3. LTR-NFkB enhancer interacts with puri®ed Tat protein and endogenously expressed Tat but not with C22G mutant Tat protein. (A) Gel shift assay
showing binding of endogenously expressed Tat in Jurkat-Tat nuclear extract to LTR NFkB oligonucleotide. Lane 1, free probe; lane 2, nuclear extract of
Jurkat-Tat; lane 3, supershift with anti-p65 (NFkB) antibody; lane 4, supershift with anti-Tat antibody; lane 5, supershift with isotype control antibody.
Arrows indicate shifted complexes. (B) Gel shift assay showing binding of NFkB complex in Jurkat nuclear extract to LTR-NFkB oligonucleotide. Lane 1,
free probe; lane 2, nuclear extract of Jurkat; lane 3, supershift with anti-p65 (NFkB) antibody. Arrows indicate shifted complexes. (C) Gel shift assay using
LTR-NFkB oligo and Jurkat nuclear extract showing speci®city of Tat antibody. Lane 1, free probe; lane 2, nuclear extract of Jurkat; lane 3, nuclear extract
of Jurkat with anti-Tat antibody. Arrows indicate shifted complexes. (D) Gel shift assay using LTR-NFkB oligonucleotide and wild-type and mutant Tat
protein. Lane 1, free probe; lane 2, wild-type Tat; lane 3, mutant Tat (C22G). Arrows indicate shifted complexes.
Table 3. List of oligonucleotide sequences obtained in SELEX experiment
using Tat protein as described in Materials and Methods
Sr. no. Sequence
1 GTGTGTTTCGCAAACAGACGCTGATCCTTAAC
2 CGAATCACACCAACCTGACGCGAAGGGATCGC
3 GTGTGTTTCGCAAACAGACGCTGATCCTTAAC
4 CGAAACACACCAACCTGACGCGAAAGGATCGC
5 GTGTGTTTCGCAAACAGACGCTGATCCTTAAC
6 CGAAACACACCAACCTGACGCGAAAGGATCGC
7 GTGTGGTTCGCAAACAGACGCTGATCCTTAAC
8 CGAACCACACCAACCTGACGCGAAAGGGTCGC
9 GCCGAAGTCTATTAAAGAGACGCTGGAAGGTG
10 AGACGCTGATCCTTAACTTACCCGGTCAGCCG
11 ACCGTGTACCACTAACGTTACCCGCAGCGTCC
12 ACCGTGTACCACTAACGTTACCCGCAGCGTCC
13 GGTGTGATTCGCAAGCAGACGCTGATCCTTAA
14 TACCGTGTACCACAACGTTACCCGCAGCGTCC
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control PCR was carried out using HIV-1 nuc-1 and nuc-2
region speci®c primers, which show a speci®c PCR product in
input control while no band was detected in anti-Tat and
isotype control (Fig. 7C). This experiment conclusively shows
the binding of Tat protein to the enhancer region of the LTR
integrated in chromatin and supports an important role for Tat
in chromatin remodeling as reported earlier (31).
DISCUSSION
Multiple regulatory elements are required for activation of
HIV-1 LTR. The activation is dominated by the Tat±TAR
interaction; however, TAR-independent activation has also
been widely reported for Tat, indicating an alternative
mechanism for Tat functions (16±19). In addition to the well
characterized ability of Tat to interact with a variety of cellular
proteins, some previous reports indicate that Tat might also act
on cognate DNA sequences in HIV-1 LTR and thereby
regulate viral gene expression (18,22,23). Using Gal4 DNA
binding domain fusion of Rel A and Tat protein, Yang et al.
(39) have suggested an alternative regulatory pathway for Tat
transactivation in speci®c cells derived from the central
nervous system. They and others have been able to show
convincingly the importance of NFkB and SP1 enhancer
elements in the LTR for TAR-independent transactivation by
Tat (18). Their data indicate that tethering of Tat onto the
enhancer region of LTR-containing NFkB and SP1 elements
is critical for TAR-independent transactivation (39). Also, Tat
is unable either to activate transcription or to induce changes
in the chromatin structure of integrated proviral promoter
lacking both SP1 and NFkB sites (25). However, no direct
DNA binding activity has been shown with native Tat protein
and the proposed cognate target remains to be identi®ed.
An initial structural homology search of the Tat protein
sequence using the hidden Markov model (37) indicates that
HIV-1 Tat shows maximal homology with mouse and human
p50 protein, a member of the NFkB family of transcription
factors. Then our gel shift data clearly indicate that, like other
DNA binding transcription factors, Tat binds to NFkB
enhancer elements of the LTR promoter sequences and
Figure 4. Position-speci®c matrix generated by MEME software analysis.
DNA sequences obtained by oligonucleotide library screening were
analyzed as described in the text. The matrix shows the bit score for the
occurrence of a particular nucleotide in the motif, total bits score as calcu-
lated and consensus obtained. The sequence derived is complementary to
NFkB enhancer-like sequence.
Figure 5. CD spectra of Tat protein in the presence of LTR-NFkB oligo-
nucleotide: solid triangles (down), CD spectrum of Tat protein, 30 mg/ml in
PBS pH 7.4; solid triangles (up), change in CD signature of Tat protein in
the presence of LTR-NFkB oligonucleotide, 0.1 nmol; open diamonds,
change in CD signature of Tat protein in the presence of mutant LTR-NFkB
oligonucleotide, 0.1 nmol; solid squares, CD signature of LTR-NFkB
oligonucleotide, 0.1 nmol; open squares, computer addition spectra of
LTR-NFkB oligonucleotide and Tat protein.
Figure 6. HIV-1 Tat protein activates NFkB enhancer driven reporter gene
expression. HEK 293T cells were transfected with pNFkB-luc (1 mg)
reporter vector (Stratagene, USA) together with either pCDNA-Tat or
pCDNA-Tat (1±48), or were stimulated with 50 ng/ml PMA. pEGFPN1 vec-
tor (Clontech, USA) was co-transfected in all experiments for normalization
based on GFP expression. Luciferase assays were performed 36 h post-
transfection using a LucliteÔ assay kit on a TopCount microplate counter
(Packard Bioscience, USA). The normalized data shown represent the mean
+ SEM of three independent experiments.
Nucleic Acids Research, 2004, Vol. 32, No. 4 1275
could also bind speci®cally to the canonical NFkB enhancer
sequence, pointing thereby to its possible role in modulating
cellular gene promoters. Tat has already been shown to
modulate the expression of several cellular genes (6,21) in the
absence of TAR-like RNA sequences and thus the NFkB
binding shown here could be one of the mechanisms involved
in the modulation. Speci®city of this interaction is obvious as
not only does Tat not bind to canonical SP1 and AP1
sequences which are important elements of LTR-mediated
gene expression, but also Tat C22G mutant failed to bind the
NFkB enhancer sequence in the LTR. CD spectra of Tat
showed the random coil type secondary structure of protein.
Although no signi®cant rearrangement of secondary structure
was noticed on binding to DNA, a de®nite and reproducible
change in CD signature was observed. This also con®rmed the
de®nite interaction between Tat and DNA. Furthermore, Tat-
induced activation of NFkB enhancer driven luciferase
expression provides functional relevance to this interaction.
Finally, an in vivo interaction of Tat with integrated LTR in
the chromatin de®nitely points toward a regulatory role for
this binding in viral gene expression. The role of Tat in both
initiation and elongation of transcription has been clearly
deciphered (2,3,10). Through its multifaceted activity, Tat has
been shown to be important in histone modi®cation which is
essential for gene expression and reactivation from latency.
Tat is shown to interact with HATs like p300 and P/CAF (11±
15), which have pleiotropic functions in chromatin modulation
and gene regulation. Interestingly, it has been proposed in a
recent report (40) that the Tat protein in the monocytic U1 cell
line is able to recruit P/CAF to promoter but lacks its own
transactivation function, resulting in a basal level of gene
expression. Addition of Tat protein in trans resulted in
enhanced reactivation of virus from latency. In this context, a
direct interaction of Tat with LTR could be hypothesized for
enhanced recruitment of HATs to viral promoter resulting in
increased transcription initiation.
Earlier reports have clearly demonstrated that Tat interacts
with SP1 (41±43) and also with cyclin T1 (9,44) and thus may
synergize to enhance the level of transactivation. Recently the
role of SP1 in recruiting cyclin T1 has been elucidated (45).
Thus, based on these previous reports, it could be said that Tat
might help in stabilizing the transcriptional complex by
bringing cyclin T1 in close proximity to SP1 or tethering of
cyclin T1 to the LTR promoter. This also indicates that SP1
plays an important role in LTR-mediated gene expression and
synergizes with Tat and may tether it to the enhancer region of
the promoter (41). Our results showing Tat±DNA interaction
could be important not only in the case of cells of neuronal
origin where TAR-independent transactivation by Tat has
been shown to have a profound effect (16,17,39), but also in
transcription initiation from the integrated provirus in other
cells. TAR-independent transactivation may also be important
due to various cell type speci®c factors, which may aid in
tethering Tat to chromatin. In light of this new information, we
propose that Tat modulates TAR-independent transactivation
by binding to NFkB enhancer sequences, and it is possible that
SP1, by binding to Tat protein, could help in tethering Tat to
its binding site on the LTR. Thus Tat binding speci®cally to
chromatin enhancer sequence elements could be the basis not
only for TAR-independent transactivation of HIV-1 LTR but
also for modulation of cellular gene promoters. Finally, this
interaction adds a new paradigm to an increasing list of
pleiotropic activities of the Tat protein.
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Figure 7. CHIP assay showing interaction of Tat with the enhancer region
of the integrated LTR in vivo in HIV-1-infected CEM-GFP cells. HIV-1
NL4.3-infected CEM-GFP cells were cross-linked by 1% formaldehyde
followed by quenching with 125 mM glycine. Cells were washed and the
pellet was lysed, followed by sonication. The sonicated lysate was pre-
cleared with protein A/G beads, salmon sperm DNA and BSA. The cleared
lysate was immunoprecipitated with anti-Tat antibody or isotype control by
incubation at 4°C overnight. The chromatin antibody complex was
immobilized on protein A/G beads and then eluted in 2% SDS, 0.1 M
NaHCO3 and 10 mM DTT. Cross-links were reversed and the protein was
digested with proteinase K (100 mg/ml). DNA was recovered by
phenol±chloroform extraction and ethanol precipitation. Precipitated DNA
was PCR ampli®ed using LTR speci®c primers (Table 2) and products were
analyzed by agarose gel electrophoresis and visualized by ethidium bromide
staining. (A) Chromatin isolated after cross-linking of infected cells was
sheared by sonication, run on agarose gel and visualized by ethidium
bromide staining (M, marker) Lane 1, sheared chromatin. (B) HIV-1 LTR
enhancer region between Nuc-0 and Nuc-1 speci®c PCR product (region:
218±393 of NL4.3) obtained by CHIP using antibody against Tat protein.
Lane 1, Tat IP; lane 2, isotype control; lane 3, Tat input control; lane 4,
isotype input control. (C) HIV-1 LTR enhancer region between Nuc-1 and
Nuc-2 speci®c PCR product (region: 643±792 of NL4.3) obtained by CHIP
using antibody against Tat protein. Lane 1, Tat IP; lane 2, isotype control;
lane 3, Tat input control; lane 4, isotype input control.
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